CD79A Antibody

What is CD79A and what is its role in B cell function?

CD79A (also known as Igα, MB-1, or MB1) is a transmembrane protein that forms a heterodimer with CD79B to constitute the signaling component of the B cell antigen receptor (BCR) complex. In humans, CD79A is a 226 amino acid protein with a mass of approximately 25 kDa that is primarily localized to the cell membrane . CD79A contains cytoplasmic immunoreceptor tyrosine-based activation motifs (ITAMs) that are crucial for transducing signals following antigen binding to the BCR .

When an antigen binds to the membrane immunoglobulin (mIg) component of the BCR, CD79A and CD79B become phosphorylated, initiating a signaling cascade that leads to B cell activation, proliferation, and differentiation . Additionally, the CD79 components are required for the internalization of the BCR complex, trafficking to late endosomes, and antigen presentation . This process is fundamental to both B cell development and immune responses.

Which cell types express CD79A and how can it be used as a marker?

CD79A is predominantly expressed in B-lineage cells as it is an essential component of the BCR. According to the search results, CD79A is notably expressed in the rectum, lymph node, colon, bone marrow, and appendix . As a marker, CD79A can be used to identify:

• B cells (including naive B cells)

• Large intestine lamina propria lymphocytes

• Regulatory T cells (in certain contexts)

• Plasma cells

The persistence of CD79A expression throughout B cell development makes it a reliable marker for identifying B cell populations in various tissues and for distinguishing B cell malignancies in histopathological analysis.

What are the key differences between anti-CD79A and anti-CD20 antibody approaches in targeting B cells?

The fundamental difference between anti-CD79A and anti-CD20 antibody approaches lies in their mechanism of action. Anti-CD20 antibodies (like rituximab) function primarily through B cell depletion, eliminating B cells from circulation for extended periods . In contrast, anti-CD79 antibodies can induce B cell anergy—a state of functional unresponsiveness—without necessarily depleting the cells .

Anti-CD79 antibody treatment leads to:

• Partial down-regulation of surface BCR

• Impaired propagation of activating signals from CD79

• Inhibition of extracellular Ca²⁺ influx

• Reduced B cell lifespan (from ~40 days to ~5 days)

This anergy-inducing approach offers a potentially less immunosuppressive therapeutic strategy compared to B cell depletion, as it functionally inhibits pathogenic B cells while potentially preserving some beneficial aspects of B cell immunity.

How do anti-CD79A antibodies induce B cell anergy at the molecular level?

Anti-CD79A antibodies induce a state resembling naturally occurring B cell anergy through several molecular mechanisms. When these antibodies bind to CD79A, they trigger chronic antigen receptor stimulation that leads to an inhibitory signaling pattern characterized by:

• Decreased expression of membrane-associated IgM and IgD on the cell surface

• Uncoupling of BCR-induced tyrosine phosphorylation cascades

• Inhibition of calcium mobilization following BCR stimulation

• Increased expression of negative regulators such as PTEN

These changes effectively render B cells unresponsive to antigens while maintaining their viability. Research indicates that anergic B cells have impaired SYK tyrosine kinase activation and disrupted signaling pathways that would normally promote B cell activation . The anergic state induced by anti-CD79 antibodies reduces the B cell lifespan significantly, from approximately 40 days to 5 days, similar to naturally occurring anergic B cells .

What experimental models are available to study human CD79A antibody therapies?

Due to limited cross-reactivity between human-targeted therapeutic antibodies and mouse CD79, researchers have developed specialized models to facilitate preclinical testing. The primary models include:

• Chimeric CD79 knockin mice: These mice have had the extracellular Ig-like domains of murine CD79A and CD79B replaced with human equivalents through gene targeting techniques . These models allow for testing of human-targeted antibodies in an in vivo system with a well-characterized immune system.

• Humanized anti-hCD79 antibodies: Researchers have developed humanized antibodies targeting human CD79 that can be tested in the chimeric mouse models. These include antibodies with mutations (such as S228P, D265A, or F234A/L235A "FALA") that reduce effector function, allowing for studies focusing on the anergy-inducing properties rather than cell depletion .

The generation of these models involved sophisticated techniques including bacterial artificial chromosome (BAC) recombineering, targeted gene replacement, and the design of specific PCR screening strategies to verify proper genetic modification .

What modifications can be made to anti-CD79A antibodies to optimize their functional properties?

Several key modifications can be made to anti-CD79A antibodies to optimize their properties for specific research or therapeutic applications:

• Fc region modifications: Mutations in the Fc region can significantly alter an antibody's effector functions. For example:

  • S228P mutation in human IgG4 antibodies stabilizes the hinge region and prevents variable light Fab arm exchange

  • D265A or F234A/L235A ("FALA") mutations reduce effector functions like antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)

• Conjugation with fluorophores: For research applications, anti-CD79A antibodies can be conjugated with fluorochromes such as APC or PE for flow cytometry and immunofluorescence applications .

• Humanization of mouse-derived antibodies: To reduce immunogenicity in potential therapeutic applications, mouse-derived antibodies can be humanized through techniques that replace mouse-specific sequences with human counterparts while preserving antigen binding specificity .

These modifications allow researchers to tailor anti-CD79A antibodies for specific experimental needs or therapeutic purposes, focusing either on B cell anergy induction or, when appropriate, depletion.

What are the optimal conditions for using anti-CD79A antibodies in flow cytometry?

When using anti-CD79A antibodies for flow cytometry, researchers should consider the following optimization steps:

• Sample preparation:

  • For blood or cell suspensions, use 1×10⁶ cells per sample

  • Block Fc receptors with anti-CD16/CD32 antibodies (for 20 minutes at 4°C) to prevent nonspecific binding

  • Perform staining in buffer containing PBS with 1-2% BSA or FBS

• Antibody selection and titration:

  • Choose appropriate fluorochrome conjugates based on your cytometer configuration and other markers in your panel

  • Common conjugates include APC and PE, which are available for anti-human CD79A antibodies

  • Perform titration experiments to determine optimal antibody concentration

• Controls:

  • Include appropriate isotype controls matched to the antibody's host species and isotype

  • For intracellular staining, include permeabilization controls

  • Consider fluorescence-minus-one (FMO) controls for multicolor panels

For intracellular staining (which may be necessary for some applications), fixation and permeabilization steps are required. Follow manufacturer-specific protocols, as the search results indicate that anti-CD79A antibodies are compatible with intracellular flow cytometry (FCM-i) .

How can researchers measure free serum anti-CD79 antibody levels in experimental models?

Researchers can measure free serum anti-CD79 antibody levels using a cell-based flow cytometric assay, as described in the search results:

• Distribute 1 million splenocytes per well in a V-bottom 96-well plate

• Block with anti-CD16/CD32 for 20 minutes at 4°C to reduce nonspecific binding

• Wash cells thoroughly

• Add 5 μl of whole mouse serum (or dilutions) to a final volume of 50 μl per well

• Incubate for 30 minutes at 4°C

• Wash cells again

• Stain with a secondary fluorescent antibody specific to the isotype of the anti-CD79 antibody (e.g., anti-mouse IgG2a)

• Analyze by flow cytometry to quantify B cell staining intensity, which correlates with the amount of anti-CD79 antibody present in the original serum

This assay provides a functional measurement of antibody levels that reflects biologically active antibody capable of binding to cellular CD79.

What approaches can be used to generate and validate CD79A knockout cells for research?

Based on the search results, the following approaches can be used to generate and validate CD79A knockout cells:

• CRISPR/Cas9 genome editing:

  • Express Cas9 in target cells (e.g., using MSCV_Cas9_puro vector)

  • Design sgRNAs targeting CD79A using tools like CHOPCHOP

  • Deliver sgRNAs by electroporation into Cas9-expressing cells

  • Verify editing efficiency by surface staining and Sanger sequencing

• Validation and clone selection:

  • Perform initial validation 72 hours post-electroporation by flow cytometry

  • Amplify targeted loci by PCR and perform Sanger sequencing

  • Analyze sequencing results using tools like TIDE software

  • Sort single cells by FACS to establish clonal populations

  • Expand clones for several weeks before repeating validation tests

• Functional validation:

  • Examine the interdependence of CD79A and CD79B for protein maturation

  • Assess IgM membrane expression levels

  • Perform competition assays to evaluate cellular fitness

  • Evaluate BCR signaling and downstream pathway activation

This systematic approach ensures the generation of well-characterized CD79A knockout cells that can serve as valuable tools for studying CD79A function and as controls for antibody specificity testing.

How effective are anti-CD79A antibodies in models of autoimmune disease?

Anti-CD79 antibodies have demonstrated significant efficacy in multiple models of autoimmune disease. According to the search results:

• Prophylactic treatment in experimental autoimmune encephalomyelitis (EAE):

  • Non-B cell-depleting anti-human CD79 antibody treatment significantly reduced disease severity

  • Treated animals showed complete recovery compared to controls

• Prevention of collagen-induced arthritis (CIA):

  • Anti-CD79b mAb was shown to prevent collagen-induced arthritis through the induction of polyclonal B cell anergy

• MRL/lpr mouse model of lupus:

  • Anti-CD79b mAb demonstrated therapeutic effectiveness in this established model of systemic lupus erythematosus

• Pristane-induced autoimmunity:

  • Anti-human CD79 antibody treatment effectively blocked pristane-induced production of anti-chromatin autoantibodies

These findings across multiple models suggest that inducing B cell anergy through CD79 targeting represents a promising therapeutic strategy for B cell-mediated autoimmune diseases without requiring complete B cell depletion.

Can anti-CD79A antibodies affect already established plasma cells, and how might this impact therapeutic applications?

The research indicates that anti-CD79A antibodies may have effects on terminally differentiated plasma cells, though these effects differ from their impact on B cells:

Evidence from the search results suggests that "anti-human CD79 treatment may inhibit Ab secretion by terminally differentiated plasmablasts and plasma cells in vitro" . This is significant because many current B cell-targeted therapies (like anti-CD20 antibodies) do not effectively target long-lived plasma cells, which continue to produce autoantibodies in autoimmune conditions even after B cell depletion.

The potential mechanism may involve:

• Inhibition of antibody secretion pathways in plasma cells

• Disruption of survival signals required by plasmablasts

• Interference with plasma cell maintenance in bone marrow niches

This finding has important implications for therapeutic applications, as it suggests anti-CD79A antibodies might address a key limitation of current B cell-targeted therapies by potentially affecting both B cells and antibody-producing plasma cells, providing more comprehensive control of autoantibody production in autoimmune diseases.

What are the differences between CD79A and CD79B as therapeutic targets?

While CD79A and CD79B function together as a heterodimer in the BCR complex, there are important considerations when targeting each specifically:

• Structural and functional differences:

  • CD79A (Igα) and CD79B (Igβ) each contain different extracellular Ig-like domains and cytoplasmic signaling elements

  • They play complementary but non-identical roles in BCR assembly and signal transduction

• Experimental evidence:

  • Much of the therapeutic data in the search results focuses on anti-CD79B antibodies, which have been shown to effectively induce B cell anergy in multiple disease models

  • Both CD79A and CD79B are required for BCR expression and signaling, suggesting that targeting either component could potentially disrupt B cell function

• Interdependence for protein maturation:

  • Research using knockout models indicates that CD79A and CD79B show interdependence for proper protein maturation and trafficking to the cell surface

  • This suggests that targeting one component might indirectly affect the other's expression and function

When designing therapeutic approaches, these differences should be considered, though targeting either CD79A or CD79B appears capable of inducing the desired anergic state in B cells for treatment of autoimmune conditions.

How can researchers distinguish between antibody-induced B cell anergy and other forms of B cell dysfunction?

Distinguishing antibody-induced B cell anergy from other forms of B cell dysfunction requires assessment of specific cellular and molecular characteristics:

• Key markers of anergic B cells:

  • Partial (not complete) down-regulation of surface BCR (IgM and IgD)

  • Uncoupling of BCR-induced tyrosine phosphorylation

  • Impaired calcium mobilization following BCR stimulation

  • Increased expression of PTEN, a negative regulator of BCR signaling

• Functional assays to confirm anergy:

  • Assess B cell response to BCR stimulation via anti-IgM antibodies

  • Measure calcium flux using fluorescent indicators

  • Quantify phosphorylation of downstream signaling molecules like SYK

  • Evaluate B cell proliferation in response to various stimuli

• Distinguishing from other states:

  • Unlike apoptotic cells, anergic B cells remain viable but unresponsive

  • Unlike activated B cells, anergic B cells show impaired, not enhanced, signaling

  • Unlike developmentally arrested B cells, anergic B cells have completed development but are functionally inhibited

These assessments help researchers confirm that the observed phenotype represents true anergy rather than other forms of B cell dysfunction or developmental arrest.

What controls should be included when evaluating anti-CD79A antibody specificity and function?

When evaluating anti-CD79A antibody specificity and function, researchers should include the following controls:

• For specificity testing:

  • CD79A knockout cells or tissue (generated using CRISPR/Cas9 as described in the search results)

  • Isotype control antibodies matched to the test antibody's host species and isotype

  • Pre-absorption controls where the antibody is pre-incubated with purified CD79A protein

  • Cross-reactivity controls using cells expressing only related proteins (e.g., CD79B)

• For functional assays:

  • Positive controls using known B cell activators (e.g., anti-IgM plus CD40L)

  • Negative controls using known B cell inhibitors

  • Dose-response curves to establish appropriate antibody concentrations

  • Time-course experiments to determine optimal treatment duration

• For in vivo experiments:

  • Vehicle-treated controls

  • Isotype control antibody treatment groups

  • Positive control treatment groups (e.g., using established therapies)

  • Measurements of serum antibody levels to confirm exposure

These comprehensive controls help ensure that observed effects are specifically attributable to anti-CD79A antibody binding and not to experimental artifacts or non-specific effects.

How might anti-CD79A antibodies be applied in cancer immunotherapy research?

Anti-CD79A antibodies hold promise for cancer immunotherapy research, particularly for B cell malignancies, through several potential mechanisms:

• Direct targeting of malignant B cells:

  • Many B cell malignancies express CD79A as part of their BCR complex

  • The search results mention that mantle cell lymphoma (MCL) cells typically overexpress IgM and associated CD79, making them potential targets

  • Anti-CD79A antibodies could induce anergy in malignant B cells, potentially reducing their proliferation and survival

• Antibody-drug conjugates (ADCs):

  • CD79A could serve as a target for ADCs that deliver cytotoxic payloads specifically to malignant B cells

  • This approach would exploit CD79A's B cell specificity while adding direct cytotoxic effects

• Chimeric antigen receptor (CAR) T cell therapy:

  • The search results mention CD79 as "an attractive target for Ab and chimeric Ag receptor T cell therapies for autoimmunity and B cell neoplasia"

  • CAR-T cells targeting CD79A could provide an alternative approach for B cell malignancies resistant to current therapies

• Combination therapies:

  • Anti-CD79A approaches might complement existing therapies by targeting different aspects of B cell biology

  • For example, combining anti-CD20 (depletion) with anti-CD79A (anergy induction) could address heterogeneous B cell populations within tumors

Further research is needed to determine the optimal applications of anti-CD79A antibodies in cancer immunotherapy, but their unique mechanism of action offers interesting possibilities beyond current approaches.

What are the potential advantages of targeting the CD79 complex compared to other B cell surface markers in next-generation therapeutics?

The CD79 complex offers several distinct advantages as a therapeutic target compared to other B cell surface markers:

• Functional inhibition without depletion:

  • Unlike anti-CD20 therapies that deplete B cells, anti-CD79 approaches can induce functional anergy without eliminating B cells

  • This may provide more selective immunomodulation with potentially fewer adverse effects

• Direct targeting of BCR signaling:

  • CD79 is directly involved in BCR signaling, so targeting it addresses a key pathogenic mechanism in B cell-mediated diseases

  • This contrasts with targeting surface markers that may not directly affect B cell function

• Potential impact on plasma cells:

  • Evidence suggests anti-CD79 treatment may inhibit antibody secretion by plasmablasts and plasma cells

  • This addresses a key limitation of anti-CD20 therapy, which generally does not affect long-lived plasma cells

• Broader therapeutic applications:

  • The anergy-inducing mechanism may be applicable across multiple autoimmune conditions

  • The research shows efficacy in models of lupus, arthritis, and multiple sclerosis

• Conservation across species:

  • CD79A orthologs have been reported in multiple species including mouse, rat, bovine, frog, zebrafish, and chimpanzee

  • This evolutionary conservation suggests fundamental importance in B cell biology and facilitates translational research

These advantages position anti-CD79 approaches as promising candidates for next-generation B cell-directed therapeutics that may offer improved selectivity and efficacy compared to current options.